Abstract:Aim: 11 beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is considered to contribute to the aetiology of the metabolic syndrome, and specific inhibitors have begun to emerge as treatments for insulin resistance and other facets of the syndrome, including atherosclerosis. Given the role of glucocorticoids and 11beta-HSD1 in the anti-inflammatory response and the involvement of inflammation in the development of atherosclerosis, 11beta-HSD1 inhibition may exacerbate atherosclerosis. Our aim was to investigate in vivo the effects of a specific 11beta-HSD1 inhibitor (2922) on atherosclerosis while assessing glucose homeostasis. Methods: We conducted a 12-week study administering 2922 (at three doses, 3, 10 and 100 mg/kg body weight) in Ldlr 3KO (Ldlr(-/-)Apob(100/100)Lep(ob/ob)) mice, a genetic model of obesity, insulin resistance, dyslipidaemia and atherosclerosis. Rosiglitazone and simvastatin were used to test the responsiveness of our model in both types of therapy. Results: 2922 was effective in reducing 11beta-HSD1 activity in inguinal adipose tissue (>90% for 100 mg/kg) and was efficacious in improving glucose homeostasis at doses > or =10 mg/kg. Plasma insulin, blood glucose, glucose tolerance and homeostatic model assessment indices were all improved in mice treated with 2922 (100 mg/kg) compared with control animals. Despite an improvement in these parameters, no differences were observed in body weight, adipose or lean tissue masses in the 2922-treated mice. Interestingly, circulating lipids, proinflammatory cytokines and atherosclerosis were unaltered in response to 2922, although a small reduction in LDL cholesterol was detected. Conclusions: Importantly, 11beta-HSD1 inhibition leads to improved glucose metabolism and does not result in a worsening of atherosclerotic lesion area, yet retained antidiabetic potential in the face of multiple severe metabolic aberrations. This study reinforces the potential use of 11beta-HSD1 inhibitors in patients with the metabolic syndrome without negatively impacting atherosclerosis.

Specific Reduction of G6PT May Contribute to Downregulation of Hepatic 11Β-Hsd1 in Diabetic Mice.

Transgenic Overexpression of Hexose-6-phosphate Dehydrogenase in Adipose Tissue Causes Local Glucocorticoid Amplification and Lipolysis in Male Mice

Interplay Between H6PDH and 11Β-Hsd1 Implicated in the Pathogenesis of Type 2 Diabetes Mellitus.

11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes

Enhanced Hexose-6-Phosphate Dehydrogenase Expression in Adipose Tissue May Contribute to Diet-Induced Visceral Adiposity

Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.

Lack of Adipose-Specific Hexose-6-phosphate Dehydrogenase Causes Inactivation of Adipose Glucocorticoids and Improves Metabolic Phenotype in Mice.

Direct Regulation of Glucose and Not Insulin on Hepatic Hexose-6-phosphate Dehydrogenase and 11Β-Hydroxysteroid Dehydrogenase Type 1

11Β-Hydroxysteroid Dehydrogenase Type 1 Shrna Ameliorates Glucocorticoid-Induced Insulin Resistance and Lipolysis in Mouse Abdominal Adipose Tissue.

The 11Β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Protects Against the Insulin Resistance and Hepatic Steatosis in Db/db Mice.

Hepatic Gadd45β Promotes Hyperglycemia and Glucose Intolerance Through DNA Demethylation of PGC-1α

11 Beta-Hydroxysteroid Dehydrogenase Type 1 Promotes Differentiation of 3T3-L1 Preadipocyte

Metabolic Crosstalk: Molecular Links Between Glycogen and Lipid Metabolism in Obesity

11 beta-hydroxysteroid dehydrogenase type 1 promotes differentiation of 3 T 3L 1 preadipocyte 1

Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis

Suppression of 11 Beta-Hydroxysteroid Dehydrogenase Type 1 with Rna Interference Substantially Attenuates 3T3-L1 Adipogenesis

Efficacious 11Beta-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model.

Reduction of Mrna M6a Associates with Glucose Metabolism Via YTHDC1 in Human and Mice.

11β-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice

Hepatic deficiency of Poldip2 in type 2 diabetes dampens lipid and glucose homeostasis.

Ectopic Lipid Deposition Mediates Insulin Resistance in Adipose Specific 11Β-Hydroxysteroid Dehydrogenase Type 1 Transgenic Mice.